WO2018187894A1 - 一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物 - Google Patents

一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物 Download PDF

Info

Publication number
WO2018187894A1
WO2018187894A1 PCT/CN2017/079856 CN2017079856W WO2018187894A1 WO 2018187894 A1 WO2018187894 A1 WO 2018187894A1 CN 2017079856 W CN2017079856 W CN 2017079856W WO 2018187894 A1 WO2018187894 A1 WO 2018187894A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
substituted
alkyl
amino
alkoxy
Prior art date
Application number
PCT/CN2017/079856
Other languages
English (en)
French (fr)
Inventor
师健友
戚宝文
Original Assignee
师健友
戚宝文
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 师健友, 戚宝文 filed Critical 师健友
Priority to PCT/CN2017/079856 priority Critical patent/WO2018187894A1/zh
Priority to CN201780062458.1A priority patent/CN109803645B/zh
Priority to US16/603,714 priority patent/US11274078B2/en
Priority to EP17905745.0A priority patent/EP3669869B1/en
Publication of WO2018187894A1 publication Critical patent/WO2018187894A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the invention relates to a medicament for treating tumor diseases and having antibacterial, antiviral and anti-inflammatory effects, in particular to a naphthalene diamide compound, a synthetic method thereof and a preliminary in vitro anti-tumor activity cell screening method, belonging to biomedicine Technical field.
  • the naphthalene diamide compound is a compound having a naphthalene ring as a basic nucleus and two amide bonds linked to the mother nucleus as a basic structure, which can be related to tumor diseases in vivo through an amide and an electron-rich group in the structure. Enzymes and receptors have an electrical effect.
  • the aromatic ring in the structure forms an aromatic ring stacking with enzymes and receptors associated with tumor diseases. Thereby achieving the purpose of treating tumor diseases.
  • Another object of the present invention is to provide a pharmaceutical compound or composition for treating an antitumor disease, which comprises a naphthalene diamide compound of the formula I, or a biologically acceptable salt or ester thereof, as It is the active ingredient.
  • the present invention provides the following technical solutions:
  • X and Y are each independently selected from a carbonyl group, a thiocarbonyl group, and a sulfonyl group.
  • R 1 and R 2 together with the nitrogen atom to which they are bonded form a ring having 3 to 12 ring atoms or a substituted ring structure substituted by a substituent M.
  • R 1 and R 2 are each independently selected from the group consisting of hydrogen, C1-C12 alkyl, C1-C12 alkoxy, C3-C7 cycloalkyl, C1-C12 alkoxycarbonyl, C1-C12 alkylcarbonyl, Aminocarbonyl, C1-C12 alkylaminocarbonyl, nitro, oxazolyl, thiazolyl, pyridyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, thiazinyl, pyrrolyl, imidazolyl, pyrazole a group, a pyrimidinyl group, a piperazinyl group, a morpholinyl group, a furyl group, a pyranyl group and other heterocyclic groups, and optionally a group substituted by a substituent M, an aryl group optionally substituted by a substituent M a benzy
  • Substituent M is hydrogen, fluorine, chlorine, bromine, iodine, cyano, nitro, hydroxy, amino, C1-C12 alkyl, halogenated C1-C12 alkyl, perfluoro C1-C12 alkyl, polyhalogenated C1 -C6 alkyl, aryl, substituted aryl, C1-C12 alkylamino, C3-C12 cycloalkylamino, di(C1-C12 alkyl)amino, C3-C12 cycloalkyl, or substituted C3-C12 ring alkyl;
  • the arylhydrocarbyl group substituted by the substituent M is a halogenated halophenyl hydrocarbyl group, an alkoxyhydrocarbyl group, a perfluorohydrocarbylphenyl hydrocarbyl group, a hydrocarbyl-substituted phenyl hydrocarbyl group, a nitro-substituted phenyl hydrocarbyl group, a hydroxy group Phenyl hydrocarbon group;
  • the heteroaryl hydrocarbon group substituted by the substituent M includes a halogenated pyridine hydrocarbon group, a halogenated furan hydrocarbon group, a halogenated thiazole hydrocarbon group, a halogenated pyrimidine hydrocarbon group, a halogenated imidazole hydrocarbon group, a nitro-substituted pyridine hydrocarbon group, Nitro-substituted furan hydrocarbyl, nitro-substituted thiazole hydrocarbyl, nitro-substituted pyrimidine hydrocarbyl, nitro-substituted imidazolidinyl, amino-substituted pyridine hydrocarbyl, amino-substituted furan hydrocarbyl, amino-substituted thiazole hydrocarbyl, amino-substituted pyrimidine a hydrocarbyl group, an amino substituted imidazolium group;
  • R3 is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, nitro, amino, C1-C3 alkyl, C1-C3 alkoxy, C3-C7 cycloalkyl, halogen-substituted C3-C7 cycloalkyl, halogen C1-C12 alkyl, C2-12 alkenyl, hydroxy substituted C1-C12 alkyl, C1-C12 alkoxy, C1-C12 alkoxycarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, di C1-C12 alkyl)aminocarbonyl, C3-C7 cycloalkylaminocarbonyl, C3-C7 cycloalkoxy, hydroxy-C1-C12 alkoxy, halogenated C1-C12 alkoxy, amino C1-C12 alkyl , amino C1-C12 alkoxy, C1-C12 al
  • R4 is selected from the group consisting of hydrogen, C1-C12 alkyl, C1-C12 alkoxy, C3-C7 cycloalkyl, halogen-substituted C3-C7 cycloalkyl, C1-C6 alkoxycarbonyl, C1-C12 alkylcarbonyl , aminocarbonyl, C1-C12 alkylaminocarbonyl, nitro, amino, C1-C3 alkyl substituted amino, di(C1-C3 alkyl) substituted amino, oxazolyl, thiazolyl, pyridyl, dihydropyridyl , tetrahydropyridyl, piperidinyl, thiazinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrimidinyl, piperazinyl, morpholinyl, furyl, pyranyl and other heterocyclic groups, and optionally The above group substituted with
  • Q is independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, cyano, nitro, hydroxy, amino, C1-C12 alkyl, halo C1-C12 alkyl, Perfluoro-C1-C12 alkyl, polyhalogenated C1-C12 alkyl, C1-C12 alkoxy, halogenated C1-C12 alkoxy, aryl, substituted aryl, C1-C12 alkylamino, C3-C7 a cycloalkylamino group, a di(C1-C12 alkyl)amino group, or a C3-C7 cycloalkyl group, substituted by a C3-C7 cycloalkyl group;
  • R5 and R6 There may be multiple R5 and R6, and a plurality of R5 and R6 are independently selected from each other.
  • the sum of the numbers of R5 and R6 is 0-6, preferably 0-3, preferably 0-2.
  • R5 and R6 When there are two or more R5 and R6, they are independent of each other.
  • R5 and R6 are each independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, nitro, hydroxy, amino, C1-C12 alkyl, C1-C12 alkoxy, C3-C7 cycloalkyl, halogenated C1.
  • -C12 alkyl C2-12 alkenyl, hydroxy substituted C1-C12 alkyl, C1-C12 alkylamino, C3-C7 cycloalkylamino, di(C1-C12 alkyl)amino, amino-C1-C12 Alkylamino, C1-C12 alkoxy C1-C12 alkylamino, C1-C12 alkoxycarbonyl, bis(C1-C12 alkoxy-C1-C12 alkyl)amino, aminocarbonyl, C1-C12 alkyl Aminocarbonyl, bis(C1-C12 alkyl)aminocarbonyl, C3-C7 cycloalkylaminocarbonyl, C3-C7 cycloalkoxy, hydroxy-C1-C12 alkoxy, halogenated C1-C12 alkoxy, amino C1-C12 alkyl, amino C1-C12 alkoxy, C1-C12 al
  • X is a carbonyl group, a thiocarbonyl group, a sulfonyl group or the like; preferably a carbonyl group.
  • Y is a carbonyl group, a thiocarbonyl group or a sulfonyl group; preferably a carbonyl group.
  • X is substituted at the ⁇ -position of the naphthalene ring, and the N-substituted N-substituent is substituted in the naphthalene ring.
  • the Y-substituted N-substitution is at the 6-position; 3 bits, then the N-connected N is substituted at 7 bits; Numbered from the C next to the two symmetric Cs (the two carbons in the middle are not numbered), where the carbons of 1, 4, 5, and 8 are exactly the same (called alpha carbon, ie alpha), 2, 3,
  • alpha carbon, ie alpha) The carbon properties of No. 6, 7 are exactly the same (called beta carbon, ie beta).
  • R 1 and R 2 together with the nitrogen atom to which they are bonded form a pyrrole ring, a tetrahydropyrrole ring, a pyridine ring, a tetrahydropyridine ring, a piperidine ring, a piperazine ring, an oxazine ring, a tetrahydrooxazine ring, or the like.
  • the ring structure formed above may be substituted by a C1-C6 alkyl group, a C1-C6 hydrocarbon group, a halogen, a halogenated C1-C3 hydrocarbon group.
  • R 1 and R 2 are each independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy, cyclopropane, cyclohexane, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, Aminocarbonyl, C1-C4 alkylaminocarbonyl, nitro, oxazolyl, thiazolyl, pyridyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, thiazinyl, pyrrolyl, imidazolyl, pyrazole A phenyl group substituted with a pyrimidyl group, a piperazinyl group, a morpholinyl group, a furyl group, a pyranyl group, a phenyl group, a C1-C4 alkyl group, and a di(C1-C4 alkyl)
  • R3 is selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, nitro, amino, methyl, ethyl, propyl, isopropyl, neobutyl, cyclopropyl, cyclohexyl, halocyclopropyl.
  • halocyclohexyl halo C1-C6 alkyl, C2-4 alkenyl, hydroxy-substituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkoxycarbonyl, aminocarbonyl, C1-C4 Alkylaminocarbonyl, bis(C1-C4 alkyl)aminocarbonyl, C3-C6 cycloalkylaminocarbonyl, C3-C6 cycloalkoxy, hydroxy-C1-C4 alkoxy, halogenated C1-C4 alkoxy , amino C1-C4 alkyl, amino C1-C4 alkoxy, C1-C4 alkyl sulfone, C2-4 alkenyl sulfone, C3-C6 cycloalkyl sulfone, heterocyclic oxy, amino-substituted piperidinyl, N-methylpiperidin-4-carbonyl,
  • R4 is selected from the group consisting of hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, cyclopropyl, cyclopentyl, cyclohexyl, halogen Substituted C3-C6 cycloalkyl, C1-C4 alkoxycarbonyl, C1-C6 alkylcarbonyl, aminocarbonyl, C1-C6 alkylaminocarbonyl, nitro, amino, C1-C3 alkyl substituted amino, di(C1 -C3 alkyl) substituted amino, oxazolyl, thiazolyl, pyridyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, thiazinyl, pyrrolyl, imidazolyl, pyrazolyl, pyrimidinyl,
  • R 5 and R 6 are hydrogen, a halogen atom, a methyl group, an ethyl group, or a propyl group.
  • R 5 and R 6 are hydrogen, and when both R 5 and R 6 are hydrogen, that is, the naphthalene ring has no substituent other than the linked diamide.
  • a preferred structure is a 4-methyl-piperazinyl group or an N-morpholinyl group.
  • R 1 and R 2 are each a methyl group.
  • R 1 and R 2 when one of R 1 and R 2 is hydrogen, the other one is selected from one of the following groups: methyl, ethyl, propyl, butyl, C1-C4 alkyl-substituted thiazolyl, thiazolyl, 2 -thiazolyl or thiazol-2-yl, C1-C4 alkyl substituted phenyl, trifluoromethylphenyl, m-trifluoromethylphenyl, C1-C4 alkyl substituted pyridyl, 6-chloro-peri Aridin-3-yl, or 2-chloropyridin-5-yl, isopropyl, cyclopropyl, cyclohexyl or cyclohexane, C1-C4 alkyl substituted cyclohexyl.
  • R 4 may be selected from the group consisting of 4-fluorophenyl, p-fluorophenyl, difluoro substituted phenyl, 3-methylphenyl, m-methylphenyl, p-methylphenyl, o-methyl Phenyl, ethylphenyl, propylphenyl, tert-butylphenyl, 2-methoxyphenyl, o-methoxyphenyl, ethoxyphenyl, di(ethoxy)phenyl, butyl Alkyl phenyl, p-methoxyphenyl, m-methoxyphenyl, m-trifluoromethylphenyl, p-trifluoromethylphenyl, 2,5-dimethoxyphenyl, m-chlorobenzene Base, p-chlorophenyl, 3,4-dichlorophenyl, trichloro substituted phenyl. And other halogen substituted pheny
  • the naphthalenediamide compound of the present invention is one of the compounds in the following table, wherein X, Y are both a carbonyl group, R 5 and R 6 are hydrogen, and R 3 is hydrogen.
  • the naphthalenediamide compound of the present invention may also be one of the compounds in the following table, wherein X, Y are each a sulfonyl group or one of them is a sulfonyl group and one is a carbonyl group, R 5 , R 6 is hydrogen or a simple alkyl group, and R 3 is hydrogen.
  • the invention also provides a process for the preparation of a compound of formula I above.
  • a method for synthesizing the above naphthalenediamide compound comprising the steps of:
  • the reaction process is as follows:
  • a medicament comprising the above compound of the formula I or a pharmaceutically acceptable salt or ester thereof as an active ingredient.
  • One or more of them may be selected as the active ingredient, and may be one compound or a plurality of compounds as an active ingredient, and the compound may be a salt or a plurality of salts, an ester or a plurality of esters as an active ingredient.
  • the above drugs are drugs for treating tumor diseases as well as having antibacterial, antiviral and anti-inflammatory effects.
  • the invention provides a novel compound having the structure of the formula I, which can effectively inhibit the growth of tumor cells, and is applied to the treatment and prevention of tumor diseases caused by abnormal growth of various human cells.
  • Figure 1 is the ABC-09 nuclear magnetic spectrum.
  • Figure 2 is the ABC-46 nuclear magnetic spectrum.
  • Lower alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, g. base.
  • Halogen includes fluoro, chloro, bromo, iodo.
  • C1-C12 alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, n-pentyl, iso-pentyl, neopentyl, sec- Base, tert-amyl, hexyl, heptyl, octyl, decyl, decyl and the like.
  • C1-C7 alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, n-pentyl, iso-pentyl, neopentyl, sec- Base, tert-amyl, hexyl, heptyl, and the like.
  • Lower alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, and the like.
  • C3-C7 cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.
  • FIG. 1 is the nuclear magnetic spectrum of compound ABC-09 and Figure 2 is the nuclear magnetic spectrum of compound ABC-46.
  • the compounds numbered AB C-51 to ABC-192 were synthesized according to the procedures of Examples 1-3, and the necessary test analysis was carried out.
  • MTT method adjust the cell lines of the cells with HCT-116, MCF-7 and A549 to 2 ⁇ 10 4 /ml with complete culture solution, inoculate them in 96-well plates, 100 ⁇ L per well, and culture overnight.
  • Cells were treated with different doses of compounds to be screened (final concentrations of 40, 20, 10, 5, 2.5, 1.25 ⁇ mol/L, respectively), while an equal volume of solvent control, DMSO concentration of 0.1% (0.1% DMSO pair) Cell proliferation has no effect).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物，该药物含有具有式I所示结构式的萘二酰胺类化合物或式I化合物的生物学可接受的盐作为活性成分。用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物对于抑制肿瘤细胞的生长作用良好，同时其也具有一定的抗菌、抗病毒和抗炎作用。

Description

一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物 技术领域
本发明涉及一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物，特别涉及一种萘二酰胺类化合物以及其合成方法、初步的体外抗肿瘤活性细胞筛选方法，属于生物医药技术领域。
背景技术
现代社会生活节奏快，人们日常工作压力大，长期处于亚健康状态。自身免疫力的不足，导致各种疾病发病率持续增高，严重威胁人类生命。20世纪以来人类对于药物的研究逐渐转向有机化学合成，其中小分子化合物以其独特的空间立体结构、电子分布、活性基团的空间排布等特点，在各种疾病治疗中发挥出了突出的作用。
萘二酰胺类化合物是以萘环为基本母核，与母核相连接的两个酰胺键为基本结构的化合物，它可以通过结构中的酰胺以及富电子基团与生物体内与肿瘤疾病相关的酶和受体发生电性作用。另一方面，结构中的芳香环与肿瘤疾病相关的酶和受体形成芳环堆叠作用。从而达到治疗肿瘤疾病的目的。
发明内容
本发明的目的在于提供了一种具有式Ⅰ结构的萘二酰胺类化合物，同时本发明还提供了制备该化合物的方法及初步的体外抗肿瘤细胞活性筛选方法。
本发明的另一目的是提供一种用于治疗抗肿瘤疾病的药物化合物或组合物，该药物化合物或组合物含有式Ⅰ萘二酰胺类化合物、或其生物学可接受的盐或酯，作为为活性成分。
为了实现上述发明目的，本发明提供了以下技术方案：
一种具有式I所示结构式的萘二酰胺类合物，
Figure PCTCN2017079856-appb-000001
Figure PCTCN2017079856-appb-000002
其中，X，Y各自独立选自羰基、硫代羰基、磺酰基。
R1、R2与连接它们的氮原子一起形成具有3-12个环原子的环或被取代基M取代的取代环结构。
或者，R1、R2各自独立的选自：氢、C1-C12烷基、C1-C12烷氧基、C3-C7环烷基、C1-C12烷氧基羰基、C1-C12烷基羰基、氨基羰基、C1-C12烷基氨基羰基、硝基、恶唑基、噻唑基、吡啶基、二氢吡啶基、四氢吡啶基、哌啶基、噻嗪基、吡咯基、咪唑基、吡唑基、嘧啶基、哌嗪基、吗啉基、呋喃基、吡喃基和其他杂环基，以及任选地被取代基M取代的上述基团，任选地被取代基M取代的芳基，任选地被取代基M取代的苄基，任选地被取代基M取代的杂芳基，任选地被取代基M取代的芳基烃基，任选地被取代基M取代的杂芳基烃基；其中，被取代基M取代时，取代基M有一个或多个；当有多个取代基M时，多个取代基M各自独立，或者其中两个取代基M相互连接形成的环结构；当两个取代基M相互连接形成环结构的时候，如果连接的被取代基M取代的基团本身也是环结构，则可以构成稠环或者不构成稠环结构。
取代基M是氢、氟、氯、溴、碘、氰基、硝基、羟基、氨基、C1-C12烷基、卤代C1-C12烷基、全氟C1-C12烷基、多卤代C1-C6烷基、芳基、取代芳基、C1-C12烷基氨基、C3-C12环烷基氨基、二(C1-C12烷基)氨基、C3-C12环烷基、或取代C3-C12环烷基；
所述被取代基M取代的芳基烃基是卤代的卤代苯基烃基、烷氧基烃基、全氟烃基苯基烃基、烃基取代的苯基烃基、硝基取代的苯基烃基、羟基取代的苯基烃基；
所述被取代基M取代的杂芳基烃基包括卤代的吡啶烃基、卤代的呋喃烃基，卤代的噻唑烃基、卤代的嘧啶烃基，卤代的咪唑烃基、硝基取代的吡啶烃基、硝基代的呋喃烃基、硝基取代的噻唑烃基、硝基取代的嘧啶烃基、硝基取代的咪唑烃基、氨基取代的吡啶烃基，氨基取代的呋喃烃基，氨基取代的噻唑烃基，氨基取代的嘧啶烃基，氨基取代的咪唑烃基；
R3选自：氢、氟、氯、溴、碘、硝基、氨基、C1-C3烷基，C1-C3烷氧基、C3-C7环烷基、卤取代的C3-C7环烷基、卤代C1-C12烷基、C2-12烯基，羟基取代的C1-C12烷基、C1-C12烷氧基、C1-C12烷氧基羰基、氨基羰基、C1-C6烷基氨基羰基、二(C1-C12烷基)氨基羰基、C3-C7环烷基氨基羰基、C3-C7环烷氧基、羟基-C1-C12烷氧基、卤代C1-C12烷氧基、氨基C1-C12烷基、氨基C1-C12烷氧基、C1-C12烷基砜、C2-12烯基砜、C3-C7环烷基砜、杂 环氧基、氨基取代的哌啶基、N-甲基哌啶-4-羰基、哌嗪-C1-C12烷基、甲酰胺基、N-甲基哌啶甲酰胺基；
R4选自：氢、C1-C12烷基、C1-C12烷氧基、C3-C7环烷基、卤取代的C3-C7环烷基、C1-C6烷氧基羰基、C1-C12烷基羰基、氨基羰基、C1-C12烷基氨基羰基、硝基、氨基、C1-C3烷基取代氨基、二(C1-C3烷基)取代氨基、恶唑基、噻唑基、吡啶基、二氢吡啶基、四氢吡啶基、哌啶基、噻嗪基、吡咯基、咪唑基、吡唑基、嘧啶基、哌嗪基、吗啉基、呋喃基、吡喃基和其他杂环基，以及任选地被取代基Q取代的上述基团，任选地被取代基Q取代的芳基，任选地被取代基Q取代的苄基，任选地被取代基Q取代的杂芳基，任选地被取代基Q取代的杂芳基烃基；其中所述被取代基Q取代，可同时被多个互不相关的Q取代，且Q为可以是各自独立的取代基，双取代时也可以是相互连接形成的环形结构。
当Q为各自独立的取代基时，Q各自独立的选自氢、氟、氯、溴、碘、氰基、硝基、羟基、氨基、C1-C12烷基、卤代C1-C12烷基、全氟C1-C12烷基、多卤代C1-C12烷基、C1-C12烷氧基、卤代C1-C12烷氧基、芳基、取代芳基、C1-C12烷基氨基、C3-C7环烷基氨基、二(C1-C12烷基)氨基、或C3-C7环烷基，取代C3-C7环烷基；
R5、R6可以有多个，多个R5、R6之间相互独立选择。R5、R6的数量之和为0-6个，优选为0-3个，最好是0-2个。当存在两个以上的R5、R6时，相互之间独立。
R5、R6为各自独立的选自：氢、氟、氯、溴、碘、硝基、羟基、氨基、C1-C12烷基，C1-C12烷氧基、C3-C7环烷基、卤代C1-C12烷基、C2-12烯基，羟基取代的C1-C12烷基、C1-C12烷基氨基、C3-C7环烷基氨基、二(C1-C12烷基)氨基、氨基-C1-C12烷基氨基、C1-C12烷氧基C1-C12烷基氨基、C1-C12烷氧基羰基、二(C1-C12烷氧基-C1-C12烷基)氨基、氨基羰基、C1-C12烷基氨基羰基、二(C1-C12烷基)氨基羰基、C3-C7环烷基氨基羰基、C3-C7环烷氧基、羟基-C1-C12烷氧基、卤代C1-C12烷氧基、氨基C1-C12烷基、氨基C1-C12烷氧基、C1-C12烷基砜、C2-12烯基砜、C3-C7环烷基砜、卤代C3-C7环烷基、杂环氧基、哌啶基氨基、N-甲基哌啶-4-羰基、哌嗪-C1-C6烷基、甲酰胺基、N-甲基哌啶甲酰胺基。
进一步，X为羰基、硫代羰基、磺酰基等；优选为羰基。
进一步，Y为羰基、硫代羰基、磺酰基；优选为羰基。
进一步，X取代在有萘环β位，且Y相连接的N取代在萘环中无取代的环对位(如X取代在2位，则Y相连接的N取代在6位；X取代在3位，则Y相连接的N取代在7位)； 从中间对称的两个C旁边的C开始编号(中间的两个碳不编号)，其中1，4，5，8号碳活性完全一样(称为α碳，即α位)，2，3，6，7号碳性质完全一样(称为β碳，即β位)。
进一步，R1、R2与连接它们的氮原子一起形成吡咯环、四氢吡咯环、吡啶环、四氢吡啶环、哌啶环、哌嗪环、噁嗪环、四氢噁嗪环、吗啉环。上述形成的环结构可以被C1-C6烷基、C1-C6烃基取代、卤素、卤代C1-C3烃基取代。
进一步，R1、R2各自独立的选自：氢、C1-C6烷基、C1-C6烷氧基、环丙烷、环己烷、C1-C4烷氧基羰基、C1-C4烷基羰基、氨基羰基、C1-C4烷基氨基羰基、硝基、恶唑基、噻唑基、吡啶基、二氢吡啶基、四氢吡啶基、哌啶基、噻嗪基、吡咯基、咪唑基、吡唑基、嘧啶基、哌嗪基、吗啉基、呋喃基、吡喃基、苯基、C1-C4烷基取代的苯基、二(C1-C4烷基)取代的苯基。
进一步，R3选自：氢、氟、氯、溴、碘、硝基、氨基、甲基、乙基、丙基、异丙基、新丁基、环丙基、环己基、卤代环丙基、卤代环己基、卤代C1-C6烷基、C2-4烯基，羟基取代的C1-C6烷基、C1-C6烷氧基、C1-C6烷氧基羰基、氨基羰基、C1-C4烷基氨基羰基、二(C1-C4烷基)氨基羰基、C3-C6环烷基氨基羰基、C3-C6环烷氧基、羟基-C1-C4烷氧基、卤代C1-C4烷氧基、氨基C1-C4烷基、氨基C1-C4烷氧基、C1-C4烷基砜、C2-4烯基砜、C3-C6环烷基砜、杂环氧基、氨基取代的哌啶基、N-甲基哌啶-4-羰基、哌嗪-C1-C12烷基、甲酰胺基、N-甲基哌啶甲酰胺基。
进一步，R4选自：氢、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、环丙基、环戊基、环己基、卤取代C3-C6环烷基、C1-C4烷氧基羰基、C1-C6烷基羰基、氨基羰基、C1-C6烷基氨基羰基、硝基、氨基、C1-C3烷基取代氨基、二(C1-C3烷基)取代氨基、恶唑基、噻唑基、吡啶基、二氢吡啶基、四氢吡啶基、哌啶基、噻嗪基、吡咯基、咪唑基、吡唑基、嘧啶基、哌嗪基、吗啉基、呋喃基、吡喃基、苯基、卤代苯基、苄基、乙基苯基、二甲基苯基、二乙基苯基、甲基(乙基)苯基、卤代苯基、卤代甲基苯基。
进一步，R5、R6为氢、卤原子、甲基、乙基、丙基。优选，R5、R6为氢，当R5、R6都是氢的时候，即萘环上除了连接的二酰胺以外没有其他的取代基。
进一步，R1、R2与连接它们的环原子一起形成具有3-8个环原子的环及取代环结构时，优选的结构为4-甲基-哌嗪基、N-吗啉基。
进一步，R1、R2均不为氢时，R1、R2均为甲基。
进一步，R1，R2其中一个为氢时，另一个选自以下基团中的一个：甲基、乙基、丙基、丁基、C1-C4烷基取代的噻唑基、噻唑基、2-噻唑基或噻唑-2-基、C1-C4烷基取代的苯基、三氟甲基苯基、间三氟甲基苯基、C1-C4烷基取代的吡啶基、6-氯-哌啶-3-基、或2-氯吡啶-5-基、异丙基、环丙基、环己基或环己烷基、C1-C4烷基取代的环己基。
进一步，R4可选自以下基团：4-氟苯基、对氟苯基、二氟取代苯基、3-甲基苯基、间甲基苯基、对甲基苯基、邻甲基苯基、乙基苯基、丙基苯基、叔丁基苯基、2-甲氧基苯基，邻甲氧基苯基、乙氧基苯基、二(乙氧基)苯基、丁基氧基苯基、对甲氧基苯基、间甲氧基苯基、间三氟甲基苯基、对三氟甲基苯基、2,5-二甲氧基苯基、间氯苯基、对氯苯基、3,4-二氯苯基、三氯取代苯基。以及其他的卤取代苯基、C1-C4烷基取代苯基、C1-C4烷氧基取代苯基、C2-C6烯基取代苯基。
进一步，更具体的来说，本发明所述的萘二酰胺化合物是以下表中化合物之一，其中X，Y均为羰基，R5、R6为氢，R3为氢。
Figure PCTCN2017079856-appb-000003
Figure PCTCN2017079856-appb-000004
Figure PCTCN2017079856-appb-000005
进一步，更具体的来说，本发明所述的萘二酰胺化合物也可为下表中的化合物之一，其中X，Y均为磺酰基或其中一个为磺酰基一个为羰基，R5、R6为氢或简单烷基，R3为氢。
Figure PCTCN2017079856-appb-000006
Figure PCTCN2017079856-appb-000007
Figure PCTCN2017079856-appb-000008
Figure PCTCN2017079856-appb-000009
Figure PCTCN2017079856-appb-000010
本发明同时还提供了一种制备上述式Ⅰ化合物的方法。
合成上述萘二酰胺类化合物的方法，包括以下步骤：
(1)取代芳香酸或其他有机羧酸在二氯亚砜为溶剂并参与反应条件下，经少量DMF催化，搅拌反应数小时，生成系列酰氯1(以下反应流程中化合物1)；
(2)随后酰氯立刻投入到羧基取代的萘胺中，该反应在THF(四氢呋喃)为溶剂，DIEA(N,N-二异丙基乙基胺)催化下进行，制得系列羧基取代萘酰胺2(以下反应流程中化合物2)；
(3)产物2与取代胺在EDCI(1-乙基-(3-二甲基氨基丙基)碳酰二亚胺)，DMAP(4-二甲氨基吡啶)催化参与下，THF为溶剂，搅拌反应得到系列萘二酰胺产物3(以下反应流程中化合物3)。
反应流程如下：
Figure PCTCN2017079856-appb-000011
一种药物，含有上述式Ⅰ化合物或其药物可接受的盐、酯作为活性成分。可以选用其中一种或多种作为活性成分，可以是一种化合物也可以是多种化合物作为活性成分，化合物可以是一种盐或多种盐、一种酯或多种酯作为活性成分。
上述药物是用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物。
与现有技术相比，本发明的有益效果：
本发明提供了一种具有式Ⅰ结构的全新化合物，可以有效的抑制肿瘤细胞的生长，应用于多种人体自身细胞异常生长导致的肿瘤疾病的治疗和预防。
附图说明：
图1是ABC-09核磁图谱。
图2是ABC-46核磁图谱。
具体实施方式
本发明中部分专业术语解释如下：
低级烷基包括但不限于甲基、乙基、丙基、异丙基、环丙基、丁基、异丁基、叔丁基、正戊基、异戊基、新戊基、己基、庚基。
卤代包括氟代，氯代，溴代，碘代。
C1-C12烷基包括但不限于：甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基、正-戊基、异-戊基、新戊基、仲戊基、叔戊基、己基、庚基、辛基、壬基、癸基等。
C1-C7烷基包括但不限于：甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基、正-戊基、异-戊基、新戊基、仲戊基、叔戊基、己基、庚基等。
低级烯基包括但不限于：乙烯基、丙烯基、丁烯基、戊烯基、己烯基、庚烯基、辛烯基等。
C3-C7环烷基包括但不限于：环丙基、环丁基、环戊基、环己基、环庚基等。
下面结合试验例及具体实施方式对本发明作进一步的详细描述。但不应将此理解为本发明上述主题的范围仅限于以下的实施例，凡基于本发明内容所实现的技术均属于本发明的范围。
实施例1
制备式1化合物
Figure PCTCN2017079856-appb-000012
取1.496g(11mmol)间甲基苯甲酸于50mL圆底烧瓶中，加入约11mL二氯亚砜，并加入3-4滴DMF催化反应，置于80℃外温回流反应3h。薄层色谱(TLC)跟踪反应进程，反应完全后，停止反应，稍冷至室温，旋转蒸发除去多余的SOCl2溶剂，得到间甲基苯甲酰氯。
实施例2
制备式2化合物
Figure PCTCN2017079856-appb-000013
取1.496g(8mmol)6-氨基萘甲酸于烧瓶中，加THF溶解，加入16mmol的DIEA，溶液于0℃下搅拌保温，将制得的间甲基苯甲酰氯溶解于DCM中，缓慢滴加至上述混合溶液。薄层色谱(TLC)跟踪反应进程，反应结束后，浓缩旋干有机相得到固体粉末，加入少量稀盐酸酸化溶液pH至弱酸性。过滤，并用水洗固体2-3次。得化合物2a粗品。
实施例3
制备式3化合物
Figure PCTCN2017079856-appb-000014
将化合物2a 76.5mg(0.25mmol)，EDCI 95mg(0.5mmol)，DMAP 30mg(0.25mmol)溶于四氢呋喃中，在室温下搅拌15min，然后加入5-氨基甲基-2-氯吡啶35.5mg(0.25mmol)继续于室温下搅拌反应约6h。停止反应，柱层分离得到产物ABC-09。
实施例4
采用实施例1-3的合成方法/思路，替换部分或全部原料，分别合成化合物ABC-1至ABC-192所示的化合物，并对其进行表征，部分化合物核磁、质谱信息如下：
ABC-01：1H-NMR(DMSO-d6,400MHz):δ11.05–10.18(m,1H),8.82–7.13(m,10H),2.50(p,J＝1.8Hz,6H),2.38(s,4H),2.23(s,2H)ppm.HRMS(ESI)m/z:(M+H)+calcd for C23H22FN3O2:390.5；found:390.2
ABC-02：1H-NMR(DMSO-d6,400MHz):δ12.73(s,1H),10.62(s,1H),8.74(d,J＝1.8Hz,1H),8.56(d,J＝2.0Hz,1H),8.19–7.90(m,6H),7.59(d,J＝3.6Hz,1H),7.46–7.25(m,3H)ppm.HRMS(ESI)m/z:(M+H)+calcd for C21H14FN3O2S:390.4；found:390.3
ABC-03：1H-NMR(DMSO-d6,400MHz):δ10.70(s,1H),10.60(s,1H),8.57(s,2H),8.30(s,1H),8.21–7.84(m,7H),7.63(t,J＝8.0Hz,1H),7.54–7.33(m,3H)ppm.HRMS(ESI)m/z:(M+H)+calcd for C25H16F4N2O2:451.4；found:451.2
ABC-04：1H-NMR(DMSO-d6,400MHz):δ8.30(d,J＝2.1Hz,1H),8.00(s,1H),7.90–7.68(m,5H),7.46–7.34(m,1H),7.19(s,1H),6.93(d,J＝8.5Hz,2H),3.82(s,3H),3.81–2.99(m,4H),2.66–2.12(m,4H),1.19(s,3H)ppm.HRMS(ESI)m/z:(M+H)+calcd for C24H25N3O3:402.5；found:402.3
ABC-05：1H-NMR(DMSO-d6,400MHz):δ10.48(s,1H),8.52(d,J＝2.0Hz,1H),8.12–7.83(m,6H),7.56–7.39(m,3H),3.33(s,3H),2.50(p,J＝1.8Hz,2H),2.39(s,5H),2.11(d,J＝99.2Hz,4H)ppm.HRMS(ESI)m/z:(M+H)+calcd for C24H25N3O2 386.5；found:386.3
ABC-06：1H-NMR(DMSO-d6,400MHz):δ10.39(s,1H),8.53(d,J＝2.0Hz,1H),3.93(s,3H),3.78(s,4H),2.55–2.49(m,5H),2.19(d,J＝12.8Hz,5H)ppm.HRMS(ESI)m/z:(M+H)+calcd for C24H25N3O3:402.5；found:402.2
ABC-07：1H-NMR(DMSO-d6,400MHz):δ10.56(s,1H),9.23(t,J＝5.9Hz,1H),8.58–8.50(m,1H),8.43(d,J＝3.4Hz,2H),8.15–7.84(m,7H),7.58–7.31(m,3H),4.54(d,J＝5.8Hz,2H)ppm.HRMS(ESI)m/z:(M+H)+calcd for C24H17ClFN3O2:432.9；found:432.2
ABC-08：1H-NMR(DMSO-d6,400MHz):δ10.39(s,1H),9.23(t,J＝6.0Hz,1H),8.47(d,J＝34.1Hz,3H),8.12–7.75(m,7H),7.50(d,J＝8.2Hz,1H),7.10(d,J＝8.5Hz,2H),4.54(d,J＝5.8Hz,2H),3.86(s,3H)ppm.HRMS(ESI)m/z:(M+H)+calcd for C25H20ClN3O3:444.9；found:444.3
ABC-09：1H-NMR(DMSO-d6,400MHz):δ10.51(s,1H),9.23(t,J＝5.9Hz,1H),8.53(d,J＝1.9Hz,1H),8.43(d,J＝2.8Hz,2H),8.08–7.75(m,8H),7.60–7.42(m,2H),4.55(d,J＝5.8Hz,2H),2.43(s,3H)ppm.HRMS(ESI)m/z:calcd for C25H20ClN3O2:428.9；found:428.3
ABC-10：1H-NMR(DMSO-d6,400MHz):δ10.43(s,1H),8.54(d,J＝2.0Hz,1H),8.43(d,J＝2.0Hz,2H),7.93(d,J＝1.2Hz,2H),7.88–7.77(m,2H),7.68(dd,J＝7.6,1.8Hz,1H),7.56–7.42(m,3H),7.31–6.95(m,3H),4.55(d,J＝5.8Hz,2H),3.93(s,3H)ppm.HRMS(ESI)m/z:(M+H)+calcd for C25H20ClN3O3:444.9；found:444.2
ABC-11：1H-NMR(DMSO-d6,400MHz):δ10.37(s,1H),8.51(d,J＝2.0Hz,1H),8.17–7.70(m,6H),7.49(dd,J＝8.4,1.7Hz,1H),7.39–6.89(m,2H),3.86(s,3H),3.48(d,J＝119.1Hz,8H)ppm.HRMS(ESI)m/z:(M+H)+calcd for C23H22N2O4:389.4；found:389.2
ABC-12：1H-NMR(DMSO-d6,400MHz):δ10.37(s,1H),8.51(d,J＝2.0Hz,1H),8.17–7.70(m,6H),7.49(dd,J＝8.4,1.7Hz,1H),7.39–6.89(m,2H),3.86(s,3H),3.48(d,J＝119.1Hz,8H)ppm.HRMS(ESI)m/z:(M+H)+calcd for C23H22N2O4:389.4；found:389.2
ABC-13：1H-NMR(DMSO-d6,400MHz):δ8.32(d,J＝2.1Hz,1H),8.07(s,1H),7.84–7.56(m,5H),7.43–7.28(m,3H),7.19(s,1H),3.66(s,8H),2.39(s,3H)ppm.HRMS(ESI)m/z:calcd for C23H22N2O3:373.4；found:373.3
ABC-14：1H-NMR(DMSO-d6,400MHz):δ10.09(s,1H),8.36(dd,J＝7.8,1.8Hz,1H),7.97–7.83(m,3H),7.66–7.45(m,3H),7.31–7.03(m,3H),4.14(s,3H),3.76(s,8H)ppm.HRMS(ESI)m/z:(M+H)+calcd for C23H22N2O4:389.4；found:389.3
ABC-15：1H-NMR(DMSO-d6,400MHz):δ10.24(s,1H),8.47(d,J＝40.5Hz,2H),8.28(s,1H),7.85(dd,J＝20.3,7.7Hz,4H),7.59(d,J＝8.9Hz,1H),7.41–7.24(m,2H),7.18–6.98(m,2H),6.80(s,1H),4.82–4.59(m,2H),4.09(d,J＝2.4Hz,3H),3.88(t,J＝1.8Hz,3H)ppm.HRMS(ESI)m/z:calcd for C26H22ClN3O4:474.9；found:474.4
部分核磁图谱如附图1-2所示，其中图1是化合物ABC-09核磁图谱，图2是化合物ABC-46核磁图谱。按照实施例1-3的方法合成制备编号为AB C-51至ABC-192的化合物，并进行必要的测试分析。
试验例
萘二酰胺类化合物的抗肿瘤细胞活性
按照实施例1-3的工艺步骤，多次合成得到表1和表2中化合物(Coupounds)并将其用于相关的抗肿瘤细胞活性试验。将上述合成的化合物采用体外培养的试验方法测试其对于HCT-116、MCF-7、Calu-6和A549肿瘤细胞的IC50浓度(MIC)，结果如下：
细胞增殖抑制实验
采用MTT法：分别用完全培养液调整细胞株为HCT-116、MCF-7、A549三种细胞细胞 浓度为2×104/ml，接种于96孔板，每孔100μL，培养过夜，次日分别用不同剂量的待筛选化合物(终浓度分别为40，20，10，5，2.5，1.25μmol/L)处理细胞，同时等体积的溶剂对照组，DMSO浓度为0.1％(0.1％的DMSO对细胞增殖没有影响)。每个设5个复孔，37℃，5％CO2培养48小时后，每孔加入5mg/ml MTT试剂20μL，继续培养2～4h，弃上清液，再加DMSO 150μL，振荡混匀15min，用酶标仪(λ＝570nm)测定吸光度(A)值(A值与活细胞数成正比)，取其平均值。相对细胞增殖抑制率(％)＝(对照组A 570-实验组A 570)/对照组A 570×100％，抑制率为50％的化合物浓度即为该化合物的IC50值。实验至少重复3次。阳性对照采用5-F脲嘧啶。结果如下：
编号 HCT-116(IC50) MCF-7(IC50) Calu-6(IC50) A549(IC50)
ABC-01        
ABC-02 10.0      
ABC-03        
ABC-04        
ABC-05 10.0      
ABC-06        
ABC-07 5.8 7.6    
ABC-08 10.0 10.9    
ABC-09 3.5 3.2    
ABC-10        
ABC-11 5.5 3.7   28.104
ABC-12        
ABC-13        
ABC-14        
ABC-15 6.6 3.5    
ABC-16        
ABC-17 3.6 3.2    
ABC-18        
ABC-19        
ABC-20 24.9 2.7    
ABC-21     48.5 48.502
ABC-22        
ABC-23        
ABC-24 5      
ABC-26 3.5      
ABC-27 38.8 2.65    
ABC-28 5.0      
ABC-29 8.0      
ABC-30        
ABC-31   3.9    
ABC-32 5.5 2.9 28.1 14.2 
ABC-33 3.0 6.6    
ABC-34 5.2 1.6    
ABC-36        
ABC-37        
ABC-38 5.0 9    
ABC-39        
ABC-40     12.4  
ABC-41        
ABC-42 20.0   7.1 3.7 
ABC-43     25.3 25.25 
ABC-44     5.5  
ABC-45 10.0 6.7 12.6 4.3 
ABC-46 2.0 6.2   1.6 
ABC-47 2.5     12.440 
ABC-48 3.9     12.629 
ABC-50        

Claims (10)

  1. 一种具有式I所示结构式的萘二酰胺类合物，
    Figure PCTCN2017079856-appb-100001
    其中，X，Y各自独立选自羰基、硫代羰基或磺酰基；
    R1、R2与连接它们的氮原子一起形成具有3-12个环原子的环或被取代基M取代的取代环结构；
    或者，R1、R2各自独立的选自：氢、C1-C12烷基、C1-C12烷氧基、C3-C7环烷基、C1-C12烷氧基羰基、C1-C12烷基羰基、氨基羰基、C1-C12烷基氨基羰基、硝基、噁唑基、噻唑基、吡啶基、二氢吡啶基、四氢吡啶基、哌啶基、噻嗪基、吡咯基、咪唑基、吡唑基、嘧啶基、哌嗪基、吗啉基、呋喃基、吡喃基和其他杂环基，以及任选地被取代基M取代的上述基团，任选地被取代基M取代的芳基，任选地被取代基M取代的苄基，任选地被取代基M取代的杂芳基，任选地被取代基M取代的芳基烃基，任选地被取代基M取代的杂芳基烃基；其中，被取代基M取代时，取代基M有一个或多个；当有多个取代基M时，多个取代基M互不相关，或者其中两个取代基M相互连接形成的环结构；当两个取代基M相互连接形成环结构的时候，如果连接的被取代基M取代的基团本身也是环结构，则可以构成稠环或者不构成稠环结构；
    取代基M是氢、氟、氯、溴、碘、氰基、硝基、羟基、氨基、C1-C12烷基、卤代C1-C12烷基、全氟C1-C12烷基、多卤代C1-C6烷基、芳基、取代芳基、C1-C12烷基氨基、C3-C12环烷基氨基、二(C1-C12烷基)氨基、C3-C12环烷基、或取代C3-C12环烷基；
    所述被取代基M取代的芳基烃基是卤代的卤代苯基烃基、烷氧基烃基、全氟烃基苯基烃基、烃基取代的苯基烃基、硝基取代的苯基烃基、羟基取代的苯基烃基；
    所述被取代基M取代的杂芳基烃基包括卤代的吡啶烃基、卤代的呋喃烃基，卤代的噻唑烃基、卤代的嘧啶烃基，卤代的咪唑烃基、硝基取代的吡啶烃基、硝基代的呋喃烃基、硝基取代的噻唑烃基、硝基取代的嘧啶烃基、硝基取代的咪唑烃基、氨基取代的吡啶烃 基，氨基取代的呋喃烃基，氨基取代的噻唑烃基，氨基取代的嘧啶烃基，氨基取代的咪唑烃基；
    R3选自：氢、氟、氯、溴、碘、硝基、氨基、C1-C3烷基，C1-C3烷氧基、C3-C7环烷基、卤取代的C3-C7环烷基、卤代C1-C12烷基、C2-12烯基，羟基取代的C1-C12烷基、C1-C12烷氧基、C1-C12烷氧基羰基、氨基羰基、C1-C6烷基氨基羰基、二(C1-C12烷基)氨基羰基、C3-C7环烷基氨基羰基、C3-C7环烷氧基、羟基-C1-C12烷氧基、卤代C1-C12烷氧基、氨基C1-C12烷基、氨基C1-C12烷氧基、C1-C12烷基砜、C2-12烯基砜、C3-C7环烷基砜、杂环氧基、氨基取代的哌啶基、N-甲基哌啶-4-羰基、哌嗪-C1-C12烷基、甲酰胺基、N-甲基哌啶甲酰胺基；
    R4选自：氢、C1-C12烷基、C1-C12烷氧基、C3-C7环烷基、卤取代的C3-C7环烷基、C1-C6烷氧基羰基、C1-C12烷基羰基、氨基羰基、C1-C12烷基氨基羰基、硝基、氨基、C1-C3烷基取代氨基、二(C1-C3烷基)取代氨基、恶唑基、噻唑基、吡啶基、二氢吡啶基、四氢吡啶基、哌啶基、噻嗪基、吡咯基、咪唑基、吡唑基、嘧啶基、哌嗪基、吗啉基、呋喃基、吡喃基和其他杂环基，以及任选地被取代基Q取代的上述基团，任选地被取代基Q取代的芳基，任选地被取代基Q取代的苄基，任选地被取代基Q取代的杂芳基，任选地被取代基Q取代的杂芳基烃基；其中所述被取代基Q取代，可同时被多个互不相关的Q取代，且Q为可以是各自独立的取代基，双取代时也可以是相互连接形成的环形结构；
    当Q为各自独立的取代基时，Q各自独立的选自氢、氟、氯、溴、碘、氰基、硝基、羟基、氨基、C1-C12烷基、卤代C1-C12烷基、全氟C1-C12烷基、多卤代C1-C12烷基、C1-C12烷氧基、卤代C1-C12烷氧基、芳基、取代芳基、C1-C12烷基氨基、C3-C7环烷基氨基、二(C1-C12烷基)氨基、或C3-C7环烷基，取代C3-C7环烷基；
    R5、R6的数量之和为0-6个；当存在两个以上的R5、R6时，相互之间独立；
    R5、R6为各自独立的选自：氢、氟、氯、溴、碘、硝基、羟基、氨基、C1-C12烷基，C1-C12烷氧基、C3-C7环烷基、卤代C1-C12烷基、C2-12烯基，羟基取代的C1-C12烷基、C1-C12烷基氨基、C3-C7环烷基氨基、二(C1-C12烷基)氨基、氨基-C1-C12烷基氨基、C1-C12烷氧基C1-C12烷基氨基、C1-C12烷氧基羰基、二(C1-C12烷氧基-C1-C12烷基)氨基、氨基羰基、C1-C12烷基氨基羰基、二(C1-C12烷基)氨基羰基、C3-C7环烷基氨基羰基、C3-C7环烷氧基、羟基-C1-C12烷氧基、卤代C1-C12烷氧基、氨基C1-C12 烷基、氨基C1-C12烷氧基、C1-C12烷基砜、C2-12烯基砜、C3-C7环烷基砜、卤代C3-C7环烷基、杂环氧基、哌啶基氨基、N-甲基哌啶-4-羰基、哌嗪-C1-C6烷基、甲酰胺基、N-甲基哌啶甲酰胺基。
  2. 根据权利要求1所述的具有式I所示结构式的萘二酰胺类合物，其特征在于，X为羰基、硫代羰基或磺酰基。
    进一步优选地，Y为羰基、硫代羰基或磺酰基。
  3. 根据权利要求1所述的具有式I所示结构式的萘二酰胺类合物，其特征在于，X取代在有萘环β位，且Y相连接的N取代在萘环中无取代的环对位。
  4. 根据权利要求1所述的具有式I所示结构式的萘二酰胺类合物，其特征在于，R1、R2与连接它们的氮原子一起形成吡咯环、四氢吡咯环、吡啶环、四氢吡啶环、哌啶环、哌嗪环、噁嗪环、四氢噁嗪环、吗啉环。
    进一步优选地，R1、R2与连接它们的环原子一起形成具有3-8个环原子的环及取代环结构时，形成的环结构是4-甲基-哌嗪基或N-吗啉基。
    或者，R1、R2各自独立的选自：氢、C1-C6烷基、C1-C6烷氧基、环丙烷、环己烷、C1-C4烷氧基羰基、C1-C4烷基羰基、氨基羰基、C1-C4烷基氨基羰基、硝基、恶唑基、噻唑基、吡啶基、二氢吡啶基、四氢吡啶基、哌啶基、噻嗪基、吡咯基、咪唑基、吡唑基、嘧啶基、哌嗪基、吗啉基、呋喃基、吡喃基、苯基、C1-C4烷基取代的苯基、二(C1-C4烷基)取代的苯基。
  5. 根据权利要求1所述的具有式I所示结构式的萘二酰胺类合物，其特征在于，R3选自：氢、氟、氯、溴、碘、硝基、氨基、甲基、乙基、丙基、异丙基、新丁基、环丙基、环己基、卤代环丙基、卤代环己基、卤代C1-C6烷基、C2-4烯基，羟基取代的C1-C6烷基、C1-C6烷氧基、C1-C6烷氧基羰基、氨基羰基、C1-C4烷基氨基羰基、二(C1-C4烷基)氨基羰基、C3-C6环烷基氨基羰基、C3-C6环烷氧基、羟基-C1-C4烷氧基、卤代C1-C4烷氧基、氨基C1-C4烷基、氨基C1-C4烷氧基、C1-C4烷基砜、C2-4烯基砜、C3-C6环烷基砜、杂环氧基、氨基取代的哌啶基、N-甲基哌啶-4-羰基、哌嗪-C1-C12烷基、甲酰胺基、N-甲基哌啶甲酰胺基。
  6. 根据权利要求1所述的具有式I所示结构式的萘二酰胺类合物，其特征在于，R4选自：氢、C1-C6烷基、卤代C1-C6烷基、C1-C6烷氧基、卤代C1-C6烷氧基、环丙基、环戊 基、环己基、卤取代C3-C6环烷基、C1-C4烷氧基羰基、C1-C6烷基羰基、氨基羰基、C1-C6烷基氨基羰基、硝基、氨基、C1-C3烷基取代氨基、二(C1-C3烷基)取代氨基、恶唑基、噻唑基、吡啶基、二氢吡啶基、四氢吡啶基、哌啶基、噻嗪基、吡咯基、咪唑基、吡唑基、嘧啶基、哌嗪基、吗啉基、呋喃基、吡喃基、苯基、卤代苯基、苄基、乙基苯基、二甲基苯基、二乙基苯基、甲基(乙基)苯基、卤代苯基、卤代甲基苯基。
    进一步优选地，R4可选自以下基团：对氟苯基、二氟取代苯基、间甲基苯基、对甲基苯基、邻甲基苯基、乙基苯基、丙基苯基、叔丁基苯基、邻甲氧基苯基、乙氧基苯基、二(乙氧基)苯基、丁基氧基苯基、对甲氧基苯基、间三氟甲基取代苯基、对三氟甲基取代苯基、2,5-二甲氧基苯基、间氯取代苯基、4-氯取代苯基、3，4-二氯取代苯基、三氯取代苯基。
  7. 根据权利要求1所述的具有式I所示结构式的萘二酰胺类合物，其特征在于，R5、R6为氢、卤原子、甲基、乙基、丙基。
  8. 根据权利要求1所述的具有式I所示结构式的萘二酰胺类合物，其特征在于，R1，R2其中一个为氢时，另一个选自以下基团中的一个：甲基、乙基、丙基、丁基、噻唑基、C1-C4烷基取代的噻唑基、噻唑-2-基、C1-C4烷基取代的苯基、C1-C4烷基取代的吡啶、三氟甲基取代苯基、2-氯吡啶-5-基、异丙基、环丙基、环己烷基、C1-C4烷基取代的环己基。
    或者，R1、R2均不为氢时，R1、R2均为甲基。
  9. 根据权利要求1所述的具有式I所示结构式的萘二酰胺类合物，其特征在于，所述的萘二酰胺化合物是以下表中化合物之一，其中X，Y均为羰基，R5、R6为氢，R3为氢；
    Figure PCTCN2017079856-appb-100002
    Figure PCTCN2017079856-appb-100003
    Figure PCTCN2017079856-appb-100004
    或者，
    式I中，其中X，Y均为磺酰基，或其中一个为磺酰基一个为羰基，R5、R6为氢或简单烷基，R3为氢；
    Figure PCTCN2017079856-appb-100005
    Figure PCTCN2017079856-appb-100006
    Figure PCTCN2017079856-appb-100007
    Figure PCTCN2017079856-appb-100008
    Figure PCTCN2017079856-appb-100009
  10. 一种药物，含有上述式Ⅰ化合物或其药物可接受的盐、酯作为活性成分。
PCT/CN2017/079856 2017-04-10 2017-04-10 一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物 WO2018187894A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/CN2017/079856 WO2018187894A1 (zh) 2017-04-10 2017-04-10 一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物
CN201780062458.1A CN109803645B (zh) 2017-04-10 2017-04-10 一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物
US16/603,714 US11274078B2 (en) 2017-04-10 2017-04-10 Drug for treating tumor diseases and having antibacterial antivirus anti-inflammatory effects
EP17905745.0A EP3669869B1 (en) 2017-04-10 2017-04-10 Drug for treating tumor diseases, and having antibacterial, antivirus and anti-inflammatory effects

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/079856 WO2018187894A1 (zh) 2017-04-10 2017-04-10 一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物

Publications (1)

Publication Number Publication Date
WO2018187894A1 true WO2018187894A1 (zh) 2018-10-18

Family

ID=63793060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/079856 WO2018187894A1 (zh) 2017-04-10 2017-04-10 一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物

Country Status (4)

Country Link
US (1) US11274078B2 (zh)
EP (1) EP3669869B1 (zh)
CN (1) CN109803645B (zh)
WO (1) WO2018187894A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010139180A1 (zh) * 2009-06-04 2010-12-09 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
CN102295635A (zh) * 2011-07-12 2011-12-28 辽宁大学 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
CN102603712A (zh) * 2012-02-14 2012-07-25 陈烨 S型和r型四氢化萘酰胺类抗肿瘤化合物和其药学上可接受的盐或前药及制备方法和应用
CN104448897A (zh) * 2014-11-20 2015-03-25 河南师范大学 末端官能化的以萘为母体的双光子荧光染料
WO2015124101A1 (zh) * 2014-02-24 2015-08-27 中国科学院上海药物研究所 萘酰胺类化合物、其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200702257B (en) * 2004-08-20 2009-06-24 Univ Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
KR20070046180A (ko) * 2004-08-20 2007-05-02 더 리젠츠 오브 더 유니버시티 오브 미시간 항세포사멸 ｂｃｌ-2군 구성원의 소분자 억제제 및 이의용도
DE102008019838A1 (de) * 2008-04-19 2009-12-10 Boehringer Ingelheim International Gmbh Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
US9006458B2 (en) * 2010-10-12 2015-04-14 Agency For Science, Technology And Research Surface Enhanced Raman Spectroscopy (SERS) compounds and methods of their preparation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010139180A1 (zh) * 2009-06-04 2010-12-09 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
CN102295635A (zh) * 2011-07-12 2011-12-28 辽宁大学 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
WO2013007184A1 (zh) * 2011-07-12 2013-01-17 Chen Ye 抗肿瘤药物四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
CN102603712A (zh) * 2012-02-14 2012-07-25 陈烨 S型和r型四氢化萘酰胺类抗肿瘤化合物和其药学上可接受的盐或前药及制备方法和应用
WO2015124101A1 (zh) * 2014-02-24 2015-08-27 中国科学院上海药物研究所 萘酰胺类化合物、其制备方法和用途
CN104448897A (zh) * 2014-11-20 2015-03-25 河南师范大学 末端官能化的以萘为母体的双光子荧光染料

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3669869A4 *

Also Published As

Publication number Publication date
CN109803645A (zh) 2019-05-24
EP3669869B1 (en) 2023-11-22
CN109803645B (zh) 2022-03-25
EP3669869C0 (en) 2023-11-22
EP3669869A4 (en) 2020-10-28
EP3669869A1 (en) 2020-06-24
US20210094910A1 (en) 2021-04-01
US11274078B2 (en) 2022-03-15

Similar Documents

Publication Publication Date Title
EP3414234B1 (en) Bruton's tyrosine kinase inhibitors
US9133122B2 (en) Amide compounds, compositions and uses thereof
JP5789259B2 (ja) 含窒素芳香族複素環誘導体
JP5916700B2 (ja) アミド化合物、組成物およびそれらの使用
AU2005332339B2 (en) Furanopyridine derivatives as ACK1 and Lck modulators
CA3051645A1 (en) Aryl hydrocarbon receptor (ahr) modulator compounds
El‐Adl et al. 5‐(4‐Methoxybenzylidene) thiazolidine‐2, 4‐dione‐derived VEGFR‐2 inhibitors: design, synthesis, molecular docking, and anticancer evaluations
TW200417546A (en) New compounds
CA2529734A1 (en) 2-amino-4-hydroxy-5-pyrimidine carboxamide derivatives and related compounds as inhibitors of t cell activation for the treatment of inflammatory diseases
EP2842955A1 (en) Trk-INHIBITING COMPOUND
EP3169687B1 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
EP2065380A1 (en) Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
WO2018234978A1 (en) SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF
ES2394324T3 (es) Piridinureas de nicotinamida como inhibidores de la cinasa del receptor del factor de crecimiento endotelial vascular (VEGF)
JP7171057B2 (ja) ヘテロアリール化合物およびその使用
CN108715585A (zh) 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
AU2006297889A1 (en) New compounds II
CA3180623A1 (en) Pyrimidine compound as axl inhibitor
WO2018187894A1 (zh) 一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物
CN106467540A (zh) 蝶啶酮衍生物作为flt3抑制剂的应用
CA2536786A1 (en) Substituted heterocyclic compounds and methods of use
AU2020414132B2 (en) Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof
US20230227428A1 (en) Amido compounds
US20100292247A1 (en) Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
KR20240066904A (ko) 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17905745

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017905745

Country of ref document: EP

Effective date: 20191111

ENP Entry into the national phase

Ref document number: 2017905745

Country of ref document: EP

Effective date: 20191111